Micropep Technologies
Micropep Technologies was incorporated in 2016 to build a unique discovery engine to rapidly identify plant bioactive peptides based on a natural, transient and localized regulation mechanism discovered by the company's scientific team. The solutions developed by Micropep unleash the natural potential of plants to help farmers better manage abiotic and biotic stresses, control weed growth and ultimately increase crop yields while preserving the environment.
Sector
Industrial Biotech
Strategy
Industrial Biotech
Status
Live
Website
www.micro-pep.com
Related News
FMC Corporation and Micropep Technologies announce strategic collaboration to co-develop bioherbicide solutions
Micropep, ag-biotech innovator, raises €8.75 million from global syndicate to bring ground-breaking and cost-effective alternatives to conventional crop protection products to market
Micropep Raises EUR 8.5M (USD 10M) in oversubscribed Series A Financing to develop innovative small peptide solutions for agriculture
Micropep Technologies Strengthens Its Management Team by Appointing Dr. Mikael Courbot as Chief Technical Officer
Micropep Technologies establishes its first Board of Directors and appoints Kevin P. Smith as Non-Executive Chairman
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.